Last edition
News about "metastatic colorectal cancer treatment"
Merck Doses First Patient in Phase 3 Trial of Investigational ADC for Colorectal Cancer
Merck announces first patient dosing in a phase 3 trial evaluating investigational Antibody Drug Conjugate (ADC) precemtabart tocentecan for metastatic colorectal cancer, targeting CEACAM5 expressed in most colorectal tumors.
Metastatic Colorectal Cancer Treatment | 22/05/2026 | By News Bureau
CuraTeQ Biologics Secures CDSCO Approval for Bevqolva
CuraTeQ Biologics receives CDSCO marketing authorisation for Bevqolva, strengthening its oncology biosimilars portfolio and expanding access to advanced cancer therapies.
Metastatic Colorectal Cancer Treatment | 16/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy